Am I Eligible for the Wegovy Pill? UK Criteria Explained

Understanding Wegovy pill eligibility can help you decide whether this treatment may be suitable for your weight management goals. The Wegovy pill contains oral semaglutide and has been approved for certain adults who meet specific UK criteria. These criteria include Body Mass Index (BMI) requirements, the presence of a weight-related health condition in some cases and an assessment by a prescriber. 

This article explains the UK criteria, the role of the MHRA licence granted to Novo Nordisk, how your medical history is reviewed, which contraindications may prevent treatment and what happens if you do not qualify [1].

In One Sentence:

Adults may be eligible for the Wegovy pill if they meet specific Wegovy pill eligibility criteria, including a qualifying Body Mass Index (BMI), relevant health factors and approval from a prescriber following a clinical assessment.

Key Takeaways

• What BMI do I need for the Wegovy pill? 

Most adults need a BMI of 30 or above, or a BMI of 27 or above with a qualifying weight-related condition.

• What counts as a weight-related condition? 

Conditions such as type 2 diabetes, high blood pressure, high cholesterol, sleep apnoea and heart disease may support eligibility.

• Is BMI the only requirement? 

No, a prescriber will also review your medical history and overall suitability.

• Can anyone be turned down despite meeting the BMI? 

Yes, factors such as medullary thyroid cancer, pancreatitis or other safety concerns may affect prescribing decisions.

• Do the thresholds differ by ethnic background? 

Yes, ethnicity-adjusted BMI thresholds may apply for some ethnic groups.

What Are the Eligibility Criteria for the Wegovy Pill in the UK?

The main eligibility criteria are based on obesity, overweight status and the presence of certain health conditions.

Under the licence granted by the MHRA, the Wegovy pill may be prescribed for an adult (aged 18 or over) with obesity and a BMI of 30 or above. It may also be suitable for adults with a BMI 27 to 29.9 if they have at least one qualifying weight-related comorbidity [1].

The qualifying weight-related conditions include type 2 diabetes, hypertension (high blood pressure), dyslipidaemia (high cholesterol), obstructive sleep apnoea and cardiovascular disease (heart disease) [2].

Like other weight management medicines, the treatment is intended to be used alongside a reduced-calorie diet and increased physical activity. Medication is generally considered one part of a wider weight management approach rather than a replacement for healthy lifestyle changes.

Do BMI Thresholds Change for Different Ethnic Backgrounds?

Yes, ethnicity-adjusted BMI thresholds may apply because obesity-related health risks can develop at lower BMI levels in some populations.

According to NICE guidance, lower BMI thresholds are often used for people from Asian, Middle Eastern, Black African and African-Caribbean backgrounds. In many cases, a reduction of 2.5 kg/m2 is applied when assessing eligibility [2].

This means that a BMI of 27.5 (obesity threshold) may be considered equivalent to a BMI of 30 in the general population. Similarly, a BMI of 24.5 (overweight with a condition) may be considered when assessing eligibility for people who also have a qualifying health condition.

These adjusted thresholds reflect the increased type 2 diabetes risk and other obesity-related health risks seen in some ethnic groups. NICE TA875 and NICE NG246 support the use of these lower thresholds when considering weight management interventions [2] [3].

A prescriber assessment remains essential, as eligibility decisions are based on your individual circumstances rather than BMI alone.

Who Cannot Take the Wegovy Weight Loss Pill?

Certain contraindications and safety concerns may mean the Wegovy weight loss pill is not suitable.

The treatment is generally not suitable for people who are pregnant, breastfeeding or planning a pregnancy. It is also not licensed for those under 18. People with a semaglutide allergy, a history of medullary thyroid cancer (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2) may not be suitable candidates.

Additional caution may be needed for people with pancreatitis, severe kidney disease or other significant medical conditions. A history of pancreatitis is particularly important because regulators have highlighted the risk of acute pancreatitis associated with GLP-1 medicines [4].

"Patient safety is always the priority. Our eligibility checks consider factors such as previous pancreatitis, thyroid cancer, medical history and other contraindications before a prescriber review is completed. These safeguards help ensure treatment is clinically appropriate for each individual."

A prescriber screening process helps identify any concerns before treatment is approved.

A Note on Eating Disorders

An active eating disorder may affect whether weight-loss medication is suitable.

People with an eating disorder such as anorexia or bulimia should discuss their situation with a GP or specialist support service before considering treatment. Weight-loss medicines may not be appropriate if there are concerns about a person's relationship with food, nutritional intake or overall wellbeing. 

Clinical assessment helps ensure the safest and most appropriate support is offered.

How Is Your Eligibility Assessed?

Eligibility is assessed through a clinical review of your health information and treatment needs.

Most private providers use an online consultation that asks for details including height, weight and medical history. This information allows a registered prescriber to calculate and confirm your BMI while reviewing any health conditions that may affect treatment suitability.

An online prescription service may also request further information if clarification is needed. If treatment is approved, the prescription can be sent to a GPhC-registered partner pharmacy for dispensing.

The tablet's Summary of Product Characteristics states that treatment should be used alongside a reduced-calorie diet and physical activity under prescriber supervision [7].

Where treatment is not suitable, alternatives may be recommended.

"The aim is to identify people with obesity or weight-related health problems who may benefit from treatment. Prescribers assess BMI, medical history and clinical appropriateness to distinguish genuine medical need from cosmetic weight loss requests."

What If You Do Not Meet the Criteria?

Not meeting the criteria does not mean there are no options available.

If you are found to be ineligible for the Wegovy pill, it is important to avoid unregulated sources that may sell fake medicines or products that have not been properly assessed for safety.

Instead, consider speaking with your GP about weight management support. Lifestyle programmes, dietary advice and specialist services can help people improve their health even when medication is not prescribed. NICE guidance outlines a range of weight management support options for people who do not receive weight-loss medicines [3].

Patient safety should always come before convenience.

Is the Wegovy Pill Available on the NHS?

At present, NHS availability differs from private prescribing arrangements.

A cost-effectiveness review by NICE has supported NHS use of the Wegovy injection within specialist weight management services under specific circumstances. However, the oral tablet is not currently funded on the NHS in the same way and may be accessed through a private online prescription service where appropriate [2].

Eligibility and local availability may change over time as further guidance is reviewed.

Can You Switch to the Pill From the Wegovy Injection?

Some patients may be able to transition from the injection to the tablet under medical supervision.

Government guidance states that people using the 2.4mg weekly injection may move directly to the 25mg daily tablet when clinically appropriate [1].

A direct transition should only take place following a prescriber-led decision. Individual circumstances, response to treatment and any required titration plans should be discussed with a healthcare professional before switching.

Frequently Asked Questions

What is the minimum age for the Wegovy pill in the UK?

The minimum age is 18 because the medicine is licensed for adults (aged 18 or over).

The current licensing does not cover children or teenagers, meaning treatment is only intended for adults who meet the relevant eligibility criteria.

Can I get the Wegovy pill if my BMI is just under 27?

In some cases, a lower threshold may apply depending on ethnic background and health factors.

The MHRA licence allows treatment for adults with a BMI of 27 alongside a qualifying condition, and some people may be assessed using a lower ethnicity-adjusted threshold. A prescriber’s decision will consider whether you have a weight-related condition and whether treatment is clinically appropriate.

Am I eligible if I have type 2 diabetes?

Type 2 diabetes may help support eligibility if BMI requirements are met.

Because type 2 diabetes is considered a weight-related condition, adults with a BMI of 27 or above may qualify under this route. A prescriber review will also consider other medicines, medical history and overall treatment suitability [1].

Can I take the Wegovy pill if I am trying to get pregnant?

The medicine is not considered suitable during pregnancy, breastfeeding or when planning a pregnancy.

Women of childbearing potential may be advised to use contraception during treatment. Anyone planning a pregnancy should discuss timing and treatment options with their prescriber before starting therapy [5].

How do I check my BMI?

You can calculate your Body Mass Index (BMI) using your height and weight.

Many people use the NHS BMI calculator or provide their measurements during an online consultation. Accurate information helps support a reliable assessment of eligibility.

Does meeting the BMI criteria guarantee I will be prescribed the pill?

Meeting the BMI threshold alone does not guarantee approval.

A prescriber approval process also considers your medical history, safety check results, current health conditions and any contraindications. Treatment is only prescribed when it is considered clinically appropriate and safe.

Final Thoughts From Our Clinical Team

“Wegovy pill eligibility depends on more than simply reaching a BMI threshold. While a BMI of 30 or a BMI of 27 with a qualifying weight-related condition may meet the core criteria, factors such as ethnicity-adjusted threshold guidance, medical history, pancreatitis, thyroid cancer, pregnancy and any eating disorder concerns also play an important role. A thorough prescriber review acts as an important safeguard to ensure treatment is suitable, safe and used alongside a healthy diet and activity changes that support long-term weight management.”

Sources

[1] First GLP-1 tablet for weight loss approved in the UK - GOV.UK

[2] 1 Recommendations | Semaglutide for managing overweight and obesity | Guidance | NICE

[3] Overweight and obesity management | Guidance | NICE

[4] GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis, including necrotising and fatal cases - GOV.UK

[5] Wegovy 25 mg tablets (Reference only - not currently marketed in the UK) - Summary of Product Characteristics (SmPC) - (emc) | 102347